Preliminary Report on Phase 1 Clinical Experience with Combined cis-diamminedichloride Platinum (II) (PDD) and 5-FU

  • R. A. Ellerby
  • F. J. Ansfield
  • H. L. Davis
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 48)


Early developments (National Cancer Institute Brochure, 1972; Rosenberg et al. [13, 14, 15]; pharmacology [1, 2, 4, 5, 7, 11, 18]) and animal tumor effectiveness ([7, 8, 12, 19, 20, 22]) have led to clinical programs [3, 16], Talley and O’Brien involving platinum derivatives. In personal communications (Schabel), discussions have centered around possible therapeutic potentiation of 5-FU by cis-platinum(II) diamminedichloride (PDD) in mouse L-1210 leukemia. As 5-FU was first synthesized and utilized clinically at the University of Wisconsin, much of our time has been spent in developing treatment modalities with 5-FU alone or in combination with other cytotoxic drugs. Certainly, we felt that potentiation of the tumoricidal action of 5-FU would not only benefit known responsive malignancies such as colon or breast adenocarcinomas, but could possibly induce increased activity towards minimally or previously unresponsive malignancies.


Chronic Lymphocytic Leukemia White Cell Count Single Daily Injection Platinum Coordination Complex Speech Discrimination Test 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Gale, G., Howle, J., Walker, E., Jr.: Antitumor and antimitogenic properties of cisdichloro(dipyridine)platinum(II). Cancer Res. 31, 950 (1971).PubMedGoogle Scholar
  2. 2.
    Harder, H., Rosenberg, B.: Inhibitory effects of anti-tumor platinum compounds on DNA, RNA, and protein synthesis in mammalian cells in vitro. Int. J. Cancer 6, 207 (1970).PubMedCrossRefGoogle Scholar
  3. 3.
    Hill, J., Speer, R., Loeb, E., Maclellan, A., Hill, N., Khan, A.: Clinical experience with cis-platinum diamminedichloride, advances in antimicrobial and antineoplastic chemotherapy, Vol. 2, p. 255. München, Berlin, Wien: Urban and Schwarzenberg 1972.Google Scholar
  4. 4.
    Howle, J., Gale, G.: Cis-dichlorodiammineplatinum(II) - Persistent and selective inhibition of deoxyribonucleic acid synthesis in vivo. Biochem. Pharmacol. 19, 2757 (1970).PubMedCrossRefGoogle Scholar
  5. 5.
    Howle, J., Thompson, H., Stone, A., Gale, G.: Cis-dichlorodiammineplatinum(II). Inhibition of nucleic acid synthesis in lymphocytes stimulated with phytohemagglutinin (35 675). Proc. Soc. exp. Biol. (N. Y.) 137, 820 (1971).Google Scholar
  6. 6.
    Kociba, R., Sleight, S.: Acute toxicologic and pathologic effects of cis-diamminedidlloroplatinum (NSC-119 875) in the male rat. Cancer Chemother. Rep. 55, 1 (1971).Google Scholar
  7. 7.
    Kociba, R., Sleight, S., Rosenberg, B.: Inhibition of dunning ascitic leukemia and Walker 256 carcinosarcoma with cis-diamminedidiloroplatinum (NSC-119 875). Cancer Chemother. Rep. 64, 325 (1970).Google Scholar
  8. 8.
    Leonard, B., Eccleston, E., Jones, D., Todd, P., Walpole, A.: Antileukemic and nephrotoxic properties of platinum compounds. Nature (Lond.) 234, 43 (1971).CrossRefGoogle Scholar
  9. 9.
    Mackman, S., Ramirez, G., Ansfield, F.: Results of 5-fluorouracil (NSC-19 893) given by the multiple daily dose method in disseminated breast cancer. Cancer Chemother. Rep. 51, 483 (1967).Google Scholar
  10. 10.
    National Cancer Institute, Brochure on cis-platinum(II) diamminedichloride (NSC-119 875) 1972.Google Scholar
  11. 11.
    Roberts, J., Pascoe, J.: Cross-linking of complementary strands of DNA in mammalian cells by antitumor platinum compounds. Nature (Lond.) 235, 282 (1972).CrossRefGoogle Scholar
  12. 12.
    Rosenberg, B., van Camp, L.: The successful regression of large solid sarcoma 180 tumors by platinum compounds. Cancer Res. 30, 1799 (1970).PubMedGoogle Scholar
  13. 13.
    Rosenberg, B., van Camp, L., Grimley, E., Thompson, A.: The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum(IV) complexes. J. biol. Chem. 242, 1347 (1967).PubMedGoogle Scholar
  14. 14.
    Rosenberg, B., van Camp, L., Krigas, T.: Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature (Lond.) 205, 698 (1965).CrossRefGoogle Scholar
  15. 15.
    Rosenberg, B., van Camp, L., Trosko, J., Mansour, V.: Platinum compounds: a new class of potent antitumor agents. Nature (Lond.) 222, 385 (1969).CrossRefGoogle Scholar
  16. 16.
    Rossof, A., Slayton, R., Perlia, C.: Preliminary clinical experience with cis-diamminedichloroplatinum(II) (NSC-119 875, CACP). Cancer (Philad.) 30, 1451 (1972).CrossRefGoogle Scholar
  17. 17.
    Schabel, F., Jr.: Unpublished data on combination chemotherapy of NSC-119 875 with NSC-19 893.Google Scholar
  18. 18.
    Shooter, K., Howse, R., Merrifield, R., Robins, A.: The interaction of platinum(II) compounds with bacteriophages T-7 and R-17. Chem.-Biol. Interactions 5, 289 (1972).Google Scholar
  19. 19.
    Sirica, A., Venditti, J., Kline, I.: Enhanced survival response of L-1210 leukemic mice. to a single combination treatment with cis-platinum(II) diamminedichloride (cis-Pt(II); NSC-119 875) plus cyclophosphamide (CY; NSC-26 271). Proc. Amer. Ass. Cancer Res. 12, 4 (1971).Google Scholar
  20. 20.
    Talley, R.: Chemotherapy of a mouse reticulum cell sarcoma with platinum salts. Proc. Amer. Ass. Cancer Res. 11, 78 (1970).Google Scholar
  21. 21.
    Talley, R., O’brien, R.: Personal communication.Google Scholar
  22. 22.
    Welsch, C.: Growth inhibition of rat mammary carcinoma induced by cis-platinum diamminedichloride(II). J. nat. Cancer Inst. 47, 1071 (1971).PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin · Heidelberg 1974

Authors and Affiliations

  • R. A. Ellerby
  • F. J. Ansfield
  • H. L. Davis

There are no affiliations available

Personalised recommendations